Deerfield Management ABEO Position
ExitedDeerfield Management exited their position in ABEONA THERAPEUTICS INC. (ABEO) in Q3 2023, after holding the stock for 3 quarters.
The position was first reported in Q1 2023 and has been tracked across 3 quarterly 13F filings.
1 other tracked fund also holds ABEO.
Short interest stands at 28.1% of float with 15.2 days to cover, indicating significant bearish positioning against the stock.
About ABEONA THERAPEUTICS INC.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Full company profile →Short Interest
28.1%
15.2 days to cover
Deerfield Management ABEO Position History
Frequently Asked Questions
Does Deerfield Management own ABEO?
No. Deerfield Management exited their position in ABEONA THERAPEUTICS INC. (ABEO) in Q3 2023. They previously held the stock for 3 quarters.
How many hedge funds own ABEO?
1 specialist biotech hedge fund currently holds ABEO, including Tang Capital Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deerfield Management first buy ABEO?
Deerfield Management's position in ABEO was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deerfield Management's ABEO position increasing or decreasing?
Deerfield Management completely exited their ABEO position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ABEOCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deerfield ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →